Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02504294 · ClinicalTrials.gov registry record · Phase 3
A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 432
- Enrollment target
NCT02504294 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 432 participants.
The verdict
NCT02504294, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 432 participants
- Enrollment target
Study Summary
A phase 3b study for subjects receiving Epogen to compare a dosing algorithm between Hospira Epoetin and Standard of Care Epogen.
Interventions
- DRUG IV Iron
- BIOLOGICAL Epoetin Hospira Arm
- OTHER Standard of Care Arm
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 432 participants |
| Start Date | 2015-07-13 |
| Est. Completion | 2016-07-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02504294
The ClinicalTrials.gov registry entry for NCT02504294 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 432 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which IV Iron is the first listed.
NCT02504294 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02504294 about?
NCT02504294 is a clinical study titled "A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis". A phase 3b study for subjects receiving Epogen to compare a dosing algorithm between Hospira Epoetin and Standard of Care Epogen.
What is the current status of trial NCT02504294?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 432 participants. The study started on 2015-07-13. Estimated completion is 2016-07-16.
What interventions are being tested in trial NCT02504294?
The interventions under investigation include: IV Iron (DRUG), Epoetin Hospira Arm (BIOLOGICAL), Standard of Care Arm (OTHER).
Who is sponsoring clinical trial NCT02504294?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.